Global Sanger Sequencing Market, By Type (Shotgun Sequencing, Targeted Gene Sequencing, and Others), By Application (Diagnostics, Personalized Medicine, Forensics, and Others), By End-use (Government Research Institutes, Diagnostic Labs, Pharmaceutical an

Sanger sequencing, also known as chain termination or dideoxy sequencing, is a method for DNA sequencing based on the selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication. This technique, developed by a British biochemist, Mr. Frederick Sanger in 1977, revolutionized DNA sequencing and enabled rapid progress in genetics and genomics. Sanger sequencing produces high-quality DNA sequences in both directions and is considered the gold standard for DNA sequencing.

Market Dynamics:

The global sanger sequencing market is predominantly driven by the increasing demand for accurate and cost-effective DNA sequencing across various industries such as healthcare, biotechnology, academic research, etc. Continuous technological advancements leading to automation and higher throughput are expanding the applications of Sanger sequencing. For example, many next-generation sequencing platforms rely on short Sanger reads for assembly. However, high capital investment requirements and complex workflow pose challenges for market growth. Emerging sequencing technologies threaten to disrupt the market through lower costs and higher capacity. Nonetheless, sanger sequencing is expected to remain relevant in niche applications that require long and accurate reads. Market players are focused on product portfolio expansion and geographic expansion through collaborations.

Key Features of the Study:

• This report provides an in-depth analysis of the global sanger sequencing market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global sanger sequencing market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study Eurofins Scientific, CeMIA, Fasteris SA, GENEWIZ , GenHunter Corporation, GenScript , LGC Biosearch Technologies, Nucleics , Quintara Biosciences, SciGenom Labs Pvt. Ltd, StarSEQ GmbH, Thermo Fisher Scientific Inc., QIAGEN, Promega Corporation, Source BioScience.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global sanger sequencing market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sanger sequencing market.

• By Type:
• Shotgun Sequencing
• Targeted Gene Sequencing
• Others
• By Application:
• Diagnostics
• Personalized Medicine
• Forensics
• Others
• By End-use:
• Government Research Institutes
• Diagnostic Labs
• Pharmaceutical and Biotechnology Company
• Others
• By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• Eurofins Scientific
• CeMIA
• Fasteris SA
• GENEWIZ
• GenHunter Corporation
• GenScript
• LGC Biosearch Technologies
• Nucleics
• Quintara Biosciences
• SciGenom Labs Pvt. Ltd
• StarSEQ GmbH
• Thermo Fisher Scientific Inc.
• QIAGEN
• Promega Corporation
• Source BioScience